Envista (NYSE:NVST) Price Target Lowered to $19.00 at Morgan Stanley

Envista (NYSE:NVST) had its target price decreased by Morgan Stanley from $20.00 to $19.00 in a report released on Thursday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

Several other brokerages also recently issued reports on NVST. Needham & Company LLC reissued a “hold” rating on shares of Envista in a research note on Thursday. Wells Fargo & Company lifted their target price on Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Thursday, February 6th. Mizuho started coverage on Envista in a research note on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective on the stock. Piper Sandler lifted their price objective on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Finally, Jefferies Financial Group lifted their price objective on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.38.

Envista Stock Down 2.2 %

NYSE NVST opened at $17.84 on Thursday. The stock’s 50-day moving average price is $20.24 and its 200-day moving average price is $19.68. The company has a market capitalization of $3.07 billion, a P/E ratio of -2.75, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. Envista has a 52 week low of $15.15 and a 52 week high of $23.00. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, equities research analysts predict that Envista will post 1 earnings per share for the current year.

Hedge Funds Weigh In On Envista

Institutional investors and hedge funds have recently modified their holdings of the stock. Huntington National Bank boosted its holdings in shares of Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares during the period. Venturi Wealth Management LLC boosted its holdings in Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after acquiring an additional 1,638 shares during the period. GAMMA Investing LLC boosted its holdings in Envista by 30.5% during the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after acquiring an additional 538 shares during the period. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Envista during the 4th quarter valued at $53,000. Finally, Mitsubishi UFJ Trust & Banking Corp purchased a new position in Envista during the 4th quarter valued at $86,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.